InfuSystem and Sanara secure exclusive US distribution deal for ChemoMouthpiece oral cryotherapy device

InfuSystem Holdings, Inc

SI Technologies, a 50/50 JV between InfuSystem and Sanara, will be exclusive US distributor of ChemoMouthpiece's FDA 510(k)-cleared oral mucositis device.
Sanara invested $5 million for a 6.6% ownership stake in ChemoMouthpiece; SI Technologies has a purchase option on the US business through January 2029.
Product targets 500,000–1,000,000 annual oral mucositis patients; estimated US market exceeds $600 million.
InfuSystem's existing oncology sales force will market the device to ~3,000 cancer centers.
AMA issued a new CPT code (effective July 2024) for reimbursement of the oral cryotherapy procedure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.